A clinical trial to compare the drug giredestrant plus palbociclib with anastrozole plus palbociclib in post-menopausal women with a specific type of early breast cancer called oestrogen receptor (ER)-positive/human growth factor 2 (HER2)-negative breast cancer
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of GDC-9545 Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer
Cancer Breast Cancer Breast Cancer Er-Positive Early Breast Cancer Breast Cancer HER-2 Negative
For the latest version of this information please go to www.forpatients.roche.com